New cocktail of three drugs targets Hard-to-Treat breast cancer

NCT ID NCT05458674

Ongoing Disease control Sponsor: Criterium, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This Phase 2 trial is testing whether a combination of three drugs—tucatinib, eribulin, and trastuzumab—is safe and effective for people with advanced HER2+ breast cancer that has not responded to prior treatments. The study will enroll 30 participants and measure tumor shrinkage, side effects, and how long the cancer stays under control. It is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tucatinib (TUKYSA), eribulin (HALAVEN), and trastuzumab (HERCEPTIN)
What this could lead to: If successful, this three-drug combination could offer a new treatment option for people with advanced HER2+ breast cancer who have already tried other therapies.
What could go wrong: This is a small, early-phase (Phase 2) trial with only 30 participants, so results may not apply to everyone. The combination may cause significant side effects, and it is not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER PRETREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HER2+ BREAST CANCER

Contacts and locations

Locations

Cancer Care Northwest

Spokane Valley, Washington, 99216, United States
George Washington Medical Faculty Associates

Washington D.C., District of Columbia, 20037, United States
New Mexico Cancer Care Alliance

Albuquerque, New Mexico, 87131, United States
Swedish Cancer Institute

Issaquah, Washington, 98029, United States
University of Colorado

Aurora, Colorado, 80045, United States
University of Wisconsin Carbone Cancer Center

Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.